Lupin Launches Generic Diabetes Drug in the US

Lupin Ltd has announced the US launch of its generic version of dapagliflozin and metformin hydrochloride extended-release tablets. The introduction follows approval from the USFDA, deeming it bioequivalent to Xigduo XR. The tablets are available in four different strengths for treating diabetes patients.

Lupin Ltd, a prominent pharmaceutical company, announced the introduction of its generic version of anti-diabetic medication dapagliflozin and metformin hydrochloride extended-release tablets in the United States.

The launch follows the approval of Lupin’s abbreviated new drug application by the US Food and Drug Administration (USFDA), confirming the drug's bioequivalence to Xigduo XR.

Available in dosages of 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, the medication aims to provide effective treatment for diabetes patients across the US.